Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Curve vs myRocky

Curve
Graded #280

Higher grade

vs+10.5
myRocky
Graded #487

Lower grade

The verdict

Curve takes it — 61.9/100 to 51.4/100.

Curve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Curve (Try Curve LLC) is a telehealth platform offering compounded semaglutide and tirzepatide, prescribed by Beluga Health providers licensed in all 50 states and dispensed by VialsRx, a US 503A…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCurve +24
58
34
Dose & formulationCurve +11
64
53
Clinical oversightCurve +4
68
64
Labs & monitoringEven
52
52
FulfillmentCurve +27
97
70
Contract termsmyRocky +21
20
41
Curve · left barmyRocky · right bar

The numbers

MetricCurvemyRocky
WeighScore61.9/10051.4/100
GradeCC
Scorecard rank#280#487
Semaglutide$175/mo (compounded)Not disclosed
Tirzepatide$225/mo (compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Curve

Graded #280 · C

Strengths

  • Offers both compounded semaglutide and tirzepatide, with every dose priced the same so cost does not rise as you titrate up.
  • LegitScript-certified (seal #51079066) and names both its 503A compounding pharmacy, VialsRx, and its provider network, Beluga Health.
  • Transparent tiered pricing with a real month-to-month option; consultation, medication, and free expedited shipping included, no membership.
  • Available in all 50 states with same-day provider review; no insurance needed and HSA/FSA accepted.

Where it loses points

  • Very new (2026 launch) with a thin track record; the site still shows a Webflow template credit and a leftover Cora reference in its Terms.
  • The cheapest headline rates ($99 semaglutide / $135 tirzepatide) require a 12-month prepay; true month-to-month is $175 and $225.
  • Both product pages currently display an out-of-stock status, so availability may be inconsistent.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard